Alison Stopeck is an Oncology physician affiliated with University of Arizona. OpenAlex indexes 299 publications with 17,910 citations (h-index 48); ClinicalTrials.gov lists 9 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 10% of Hematology / Oncology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2701 E Elvira Rd
Tucson, AZ 857067124
Telephone
520-874-3500Registry record last updated 2 Feb 2012.
Clinical trials
- Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer
Sponsor: Alison Stopeck
- Sulindac and Breast Density in Women at Risk of Developing Breast Cancer
Sponsor: Alison Stopeck
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
18 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20253 payments
- Sandoz Inc.Program year20251 payment
- PFIZER INC.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
4 NIH research awards on record, funded 1992–2014 per NIH RePORTER. The latest:
- Nsaid Effects on Clinical and Imaging Breast Biomarkers
University of Arizona
FY2014$138,298R01CA161534 - Nsaid Effects on Clinical and Imaging Breast Biomarkers
University of Arizona
FY2013$584,187R01CA161534 - Nsaid Effects on Clinical and Imaging Breast Biomarkers
University of Arizona
FY2012$400,797R01CA161534
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval
Journal of bone oncology
2022 - Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307
JNCI Journal of the National Cancer Institute
2019 - A randomized, placebo-controlled trial of diindolylmethane for breast cancer biomarker modulation in patients taking tamoxifen
Breast Cancer Research and Treatment
2017
Similar KOLs
Other experts from the same institution or the same specialty.
Joseph Alpert, MD
University of Arizona
Karl Kern, MD
University of Arizona
Peter Reaven, MD
University of Arizona
Sairam Parthasarathy, MD
University of Arizona
Carl June, MD
University of Pennsylvania
Christopher Benz, MD
Buck Institute for Research on Aging
Christina Fitzmaurice, MD
Gundersen Health System
Beth Karlan, MD
Cedars-Sinai Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”